Aura Biosciences, Inc. Research and Development Expense
Aura Biosciences, Inc. (AURA) reported Research and Development Expense of $30.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Aura Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $30.75M, a 34.38% increase year-over-year.
- Aura Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $27.96M, a 19.78% increase year-over-year.
- Aura Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $21.90M, a 1.96% decline year-over-year.
- Aura Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $22.18M, a 30.18% increase year-over-year.
- Aura Biosciences, Inc. research and development expense for fiscal 2025 was $90.30M, a 23.19% increase from fiscal 2024.
- Aura Biosciences, Inc. research and development expense for fiscal 2024 was $73.30M, a 12.37% increase from fiscal 2023.
- Aura Biosciences, Inc. research and development expense for fiscal 2023 was $65.23M, a 54.44% increase from fiscal 2022.
- Aura Biosciences, Inc. research and development expense for fiscal 2022 was $42.24M, a 67.87% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.75M 10-Q · filed 2026-08-11 | $58.71M 10-Q · filed 2026-08-11 | $80.61M derived: sum of 3 quarters · filed 2026-08-11 | $102.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $27.96M 10-Q · filed 2026-05-11 | $49.86M derived: sum of 2 quarters · filed 2026-05-11 | $72.03M derived: sum of 3 quarters · filed 2026-05-11 | $94.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $21.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $44.08M derived: sum of 2 quarters · filed 2026-03-30 | $66.96M derived: sum of 3 quarters · filed 2026-08-11 | $90.30M 10-K · filed 2026-03-30 |
| 2025-09-30 | $22.18M 10-Q · filed 2025-11-13 | $45.06M derived: sum of 2 quarters · filed 2026-08-11 | $68.40M 10-Q · filed 2025-11-13 | $90.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $22.88M 10-Q · filed 2026-08-11 | $46.23M 10-Q · filed 2026-08-11 | $68.56M derived: sum of 3 quarters · filed 2026-08-11 | $85.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $23.34M 10-Q · filed 2026-05-11 | $45.68M derived: sum of 2 quarters · filed 2026-05-11 | $62.71M derived: sum of 3 quarters · filed 2026-05-11 | $79.59M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $22.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $39.37M derived: sum of 2 quarters · filed 2026-03-30 | $56.25M derived: sum of 3 quarters · filed 2026-03-30 | $73.30M 10-K · filed 2026-03-30 |
| 2024-09-30 | $17.04M 10-Q · filed 2025-11-13 | $33.91M derived: sum of 2 quarters · filed 2025-11-13 | $50.97M 10-Q · filed 2025-11-13 | $71.25M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $16.88M 10-Q · filed 2025-08-13 | $33.93M 10-Q · filed 2025-08-13 | $54.21M derived: sum of 3 quarters · filed 2025-08-13 | $69.64M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $17.05M 10-Q · filed 2025-05-15 | $37.33M derived: sum of 2 quarters · filed 2025-05-15 | $52.76M derived: sum of 3 quarters · filed 2025-05-15 | $67.88M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $35.71M derived: sum of 2 quarters · filed 2025-03-24 | $50.83M derived: sum of 3 quarters · filed 2025-03-24 | $65.23M 10-K · filed 2025-03-24 |
| 2023-09-30 | $15.43M 10-Q · filed 2024-11-12 | $30.55M derived: sum of 2 quarters · filed 2024-11-12 | $44.95M 10-Q · filed 2024-11-12 | $58.11M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $15.12M 10-Q · filed 2024-08-08 | $29.52M 10-Q · filed 2024-08-08 | $42.68M derived: sum of 3 quarters · filed 2024-08-08 | $53.98M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $14.40M 10-Q · filed 2024-05-09 | $27.56M derived: sum of 2 quarters · filed 2024-05-09 | $38.86M derived: sum of 3 quarters · filed 2024-05-09 | $48.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $13.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $24.45M derived: sum of 2 quarters · filed 2024-03-27 | $33.96M derived: sum of 3 quarters · filed 2024-03-27 | $42.24M 10-K · filed 2024-03-27 |
| 2022-09-30 | $11.29M 10-Q · filed 2023-11-09 | $20.80M derived: sum of 2 quarters · filed 2023-11-09 | $29.08M 10-Q · filed 2023-11-09 | $37.06M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.51M 10-Q · filed 2023-08-09 | $17.79M 10-Q · filed 2023-08-09 | $25.77M derived: sum of 3 quarters · filed 2023-08-09 | $32.13M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $8.28M 10-Q · filed 2023-05-11 | $16.25M derived: sum of 2 quarters · filed 2023-05-11 | $22.62M derived: sum of 3 quarters · filed 2023-05-11 | $29.25M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $14.34M derived: sum of 2 quarters · filed 2023-03-15 | $20.98M derived: sum of 3 quarters · filed 2023-03-15 | $25.16M 10-K · filed 2023-03-15 |
| 2021-09-30 | $6.37M 10-Q · filed 2022-11-10 | $13.00M derived: sum of 2 quarters · filed 2022-11-10 | $17.18M 10-Q · filed 2022-11-10 | $20.73M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $6.63M 10-Q · filed 2022-08-11 | $10.82M 10-Q · filed 2022-08-11 | $14.36M derived: sum of 3 quarters · filed 2022-08-11 | $17.21M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.18M 10-Q · filed 2022-05-12 | $7.73M derived: sum of 2 quarters · filed 2022-05-12 | $10.58M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $6.39M derived: sum of 2 quarters · filed 2022-03-23 | $18.04M 10-K · filed 2022-03-23 | |
| 2020-09-30 | $2.85M 10-Q · filed 2021-11-24 | $14.50M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |